HUP0100186A2 - Laktám típusú metalloproteináz-gátló vegyületek és az ilyen vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Laktám típusú metalloproteináz-gátló vegyületek és az ilyen vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0100186A2 HUP0100186A2 HU0100186A HUP0100186A HUP0100186A2 HU P0100186 A2 HUP0100186 A2 HU P0100186A2 HU 0100186 A HU0100186 A HU 0100186A HU P0100186 A HUP0100186 A HU P0100186A HU P0100186 A2 HUP0100186 A2 HU P0100186A2
- Authority
- HU
- Hungary
- Prior art keywords
- ring
- group
- compounds
- diseases
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 150000003951 lactams Chemical class 0.000 title 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910020008 S(O) Inorganic materials 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 108010003059 aggrecanase Proteins 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre vonatkozik, amelyekegy szűkebb, a hatásos anyagokat főként képviselő csoportját alkotjáka (II) általános képletű vegyületek, sztereoizomerjeik és azokgyógyászati szempontból elfogadható sói, ahol a (II) képletben Ajelentése -CO2H, -CH2CO2H, -CONHOH vagy -CONHOR5általános képletűcsoport; a C gyűrű a G gyűrűvel kondenzálva van; a C gyűrű fenilgyűrű,vagy aromás heterociklus, amely heteroatomként oxigén-, nitrogénatomotvagy S(O)p csoportot tartalmaz, és a C gyűrű 1 R1' csoporttalszubsztituált; a G gyűrű 0-1 karbonilcsoporttal szubsztituált,karbociklusos gyűrű; alternatív módon a G gyűrű heterociklusos gyűrű,amely 1-2 heteroatomként oxigénatomot vagy NRa csoportot tartalmaz, 0-2 karbonilcsoporttal szubsztituált és 0-1 kettős kötése van; Atalálmány szerinti hatóanyagok gátolják a metalloproteináz enzimeket,a tumor-nekrózis faktort és az aggrekanáz enzimet, és ennek alapjánvárhatóan ezen enzimek által közvetített betegségek kezelésére vagymegelőzésére alkalmazhatók. Ilyen betegségek terápiája szempontjábólelsősorban gyulladásos betegségek, reumás izületi gyulladás,csontizületi gyulladás, valamint daganatáttételek kezelése ésmegelőzése vehető számításba. A találmány a fenti hatóanyagokattartalmazó gyógyászati készítményekre, valamint ezeknek az anyagoknakaz alkalmazására is vonatkozik a fenti betegségek gyógyításáraalkalmazható gyógyszerek előállításában. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6241897P | 1997-10-03 | 1997-10-03 | |
PCT/US1998/021037 WO1999018074A1 (en) | 1997-10-03 | 1998-10-02 | Novel lactam metalloprotease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0100186A2 true HUP0100186A2 (hu) | 2001-05-28 |
HUP0100186A3 HUP0100186A3 (en) | 2002-12-28 |
Family
ID=22042365
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0100186A HUP0100186A3 (en) | 1997-10-03 | 1998-10-02 | Compounds as lactam metalloprotease inhibitors and pharmaceutical compositions containing them |
Country Status (25)
Country | Link |
---|---|
US (1) | US6057336A (hu) |
EP (1) | EP1027332B1 (hu) |
JP (1) | JP2001519331A (hu) |
KR (1) | KR20010015690A (hu) |
CN (1) | CN1272841A (hu) |
AR (1) | AR017291A1 (hu) |
AT (1) | ATE267805T1 (hu) |
AU (1) | AU747239B2 (hu) |
BR (1) | BR9815398A (hu) |
CA (1) | CA2305679A1 (hu) |
DE (1) | DE69824199T2 (hu) |
DK (1) | DK1027332T3 (hu) |
EE (1) | EE200000199A (hu) |
ES (1) | ES2217592T3 (hu) |
HR (1) | HRP980533A2 (hu) |
HU (1) | HUP0100186A3 (hu) |
IL (1) | IL135289A0 (hu) |
NO (1) | NO315648B1 (hu) |
NZ (1) | NZ504088A (hu) |
PL (1) | PL339738A1 (hu) |
PT (1) | PT1027332E (hu) |
SK (1) | SK4462000A3 (hu) |
TW (1) | TW541304B (hu) |
WO (1) | WO1999018074A1 (hu) |
ZA (1) | ZA988967B (hu) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
WO2000059285A2 (en) | 1999-04-02 | 2000-10-12 | Du Pont Pharmaceuticals Company | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE |
EP1180513A4 (en) * | 1999-04-28 | 2002-07-10 | Takeda Chemical Industries Ltd | CYCLIC AMID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
ATE356114T1 (de) | 1999-06-04 | 2007-03-15 | Astrazeneca Ab | Inhibitoren von metalloproteinasen |
US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
US6620823B2 (en) * | 2000-07-11 | 2003-09-16 | Bristol-Myers Squibb Pharme Company | Lactam metalloprotease inhibitors |
GB0119474D0 (en) * | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
GB0127568D0 (en) | 2001-11-16 | 2002-01-09 | Glaxo Group Ltd | Chemical compounds |
PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
AU2003214231A1 (en) * | 2002-03-22 | 2003-10-13 | Bristol-Myers Squibb Company | Dpc 333 formulation having unique biopharmaceutical characteristics |
US20030225054A1 (en) * | 2002-06-03 | 2003-12-04 | Jingwu Duan | Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents |
WO2003104220A1 (en) * | 2002-06-11 | 2003-12-18 | Bristol-Myers Squibb Company | Asymetric synthesis of amino-pyrrolidinones |
WO2004002956A2 (en) * | 2002-06-28 | 2004-01-08 | Bristol Myers Squibb Company | Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
JP4799408B2 (ja) * | 2003-07-15 | 2011-10-26 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 新規な2−オキソ複素環化合物およびそれを含有する薬剤組成物の使用 |
US7723376B2 (en) | 2003-07-15 | 2010-05-25 | Korea Research Institute Of Bioscience And Biotechnology | 2-oxo-heterocyclic compounds and pharmaceutical compositions |
US20090192191A1 (en) * | 2004-01-09 | 2009-07-30 | Braj Bhushan Lohray | Substituted hydroxamic acid derivatives as tnf inhibitors |
DK2041181T3 (da) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi |
TWI539947B (zh) * | 2007-04-09 | 2016-07-01 | 米希爾金尼公司 | 組蛋白去乙醯基酶之抑制劑 |
WO2009094427A1 (en) | 2008-01-23 | 2009-07-30 | Bristol-Myers Squibb Company | 4-pyridinone compounds and their use for cancer |
WO2009118175A1 (en) | 2008-03-25 | 2009-10-01 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
US8580859B2 (en) | 2008-08-01 | 2013-11-12 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
CA2986195A1 (en) | 2009-03-25 | 2010-09-30 | Abbvie Inc. | Substituted aryl antivrial compounds and uses thereof |
CN102395562A (zh) | 2009-04-14 | 2012-03-28 | 阿费克蒂斯制药股份公司 | 新的p2x7r拮抗剂及其用途 |
US20130338061A1 (en) * | 2010-10-08 | 2013-12-19 | Lipa Shah | Salts and Polymorphs of Sulfamide NS3 Inhibitors |
WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Gpr119アゴニスト活性を有するスピロ誘導体 |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
ES2748940T3 (es) | 2011-11-11 | 2020-03-18 | Univ Yale | Evaluación de la presencia de una fibrilación auricular y de la vulnerabilidad a ésta, y otras indicaciones sobre la base de la toma de imágenes basada en metaloproteinasas de matriz |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5318964A (en) * | 1992-06-11 | 1994-06-07 | Hoffmann-La Roche Inc. | Hydroxamic derivatives and pharmaceutical compositions |
GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
GB9307956D0 (en) * | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
AU7604196A (en) * | 1995-10-30 | 1997-05-22 | Merck & Co., Inc. | Novel inhibitors of peptide binding to mhc class ii proteins |
TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
-
1998
- 1998-10-01 ZA ZA9808967A patent/ZA988967B/xx unknown
- 1998-10-02 BR BR9815398-6A patent/BR9815398A/pt not_active IP Right Cessation
- 1998-10-02 AT AT98950954T patent/ATE267805T1/de not_active IP Right Cessation
- 1998-10-02 HR HR60/062,418A patent/HRP980533A2/hr not_active Application Discontinuation
- 1998-10-02 PT PT98950954T patent/PT1027332E/pt unknown
- 1998-10-02 SK SK446-2000A patent/SK4462000A3/sk unknown
- 1998-10-02 US US09/165,747 patent/US6057336A/en not_active Expired - Lifetime
- 1998-10-02 AU AU96866/98A patent/AU747239B2/en not_active Ceased
- 1998-10-02 EP EP98950954A patent/EP1027332B1/en not_active Expired - Lifetime
- 1998-10-02 DK DK98950954T patent/DK1027332T3/da active
- 1998-10-02 DE DE69824199T patent/DE69824199T2/de not_active Expired - Lifetime
- 1998-10-02 CN CN98809703A patent/CN1272841A/zh active Pending
- 1998-10-02 CA CA002305679A patent/CA2305679A1/en not_active Abandoned
- 1998-10-02 IL IL13528998A patent/IL135289A0/xx unknown
- 1998-10-02 EE EEP200000199A patent/EE200000199A/xx unknown
- 1998-10-02 AR ARP980104945A patent/AR017291A1/es not_active Application Discontinuation
- 1998-10-02 ES ES98950954T patent/ES2217592T3/es not_active Expired - Lifetime
- 1998-10-02 KR KR1020007003563A patent/KR20010015690A/ko not_active Application Discontinuation
- 1998-10-02 HU HU0100186A patent/HUP0100186A3/hu unknown
- 1998-10-02 NZ NZ504088A patent/NZ504088A/en unknown
- 1998-10-02 JP JP2000514886A patent/JP2001519331A/ja not_active Withdrawn
- 1998-10-02 WO PCT/US1998/021037 patent/WO1999018074A1/en not_active Application Discontinuation
- 1998-10-02 PL PL98339738A patent/PL339738A1/xx unknown
- 1998-10-21 TW TW087116499A patent/TW541304B/zh active
-
2000
- 2000-02-17 NO NO20000783A patent/NO315648B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
SK4462000A3 (en) | 2002-06-04 |
PT1027332E (pt) | 2004-08-31 |
NO20000783L (no) | 2000-05-29 |
WO1999018074A1 (en) | 1999-04-15 |
HUP0100186A3 (en) | 2002-12-28 |
JP2001519331A (ja) | 2001-10-23 |
DE69824199D1 (de) | 2004-07-01 |
AR017291A1 (es) | 2001-09-05 |
AU747239B2 (en) | 2002-05-09 |
AU9686698A (en) | 1999-04-27 |
PL339738A1 (en) | 2001-01-02 |
US6057336A (en) | 2000-05-02 |
TW541304B (en) | 2003-07-11 |
ATE267805T1 (de) | 2004-06-15 |
NO20000783D0 (no) | 2000-02-17 |
NZ504088A (en) | 2001-09-28 |
ZA988967B (en) | 2000-04-03 |
EP1027332A1 (en) | 2000-08-16 |
ES2217592T3 (es) | 2004-11-01 |
DK1027332T3 (da) | 2004-10-04 |
EP1027332B1 (en) | 2004-05-26 |
BR9815398A (pt) | 2000-10-31 |
DE69824199T2 (de) | 2005-01-27 |
IL135289A0 (en) | 2001-05-20 |
EE200000199A (et) | 2001-04-16 |
HRP980533A2 (en) | 1999-10-31 |
CA2305679A1 (en) | 1999-04-15 |
NO315648B1 (no) | 2003-10-06 |
KR20010015690A (ko) | 2001-02-26 |
CN1272841A (zh) | 2000-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0100186A2 (hu) | Laktám típusú metalloproteináz-gátló vegyületek és az ilyen vegyületeket tartalmazó gyógyászati készítmények | |
GB2303629B (en) | Hydroxamic acids and their use as metalloproteinase inhibitors | |
NO963499L (no) | Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav | |
ATE438380T1 (de) | Protonenpumpeninhibitoren enthaltendes arzneimittel | |
DE3686483T2 (de) | Arzneimittel. | |
MA23170A1 (fr) | Procede de preparation d'un nouveau compose . | |
NO302474B1 (no) | Sakarinderivater, farmasöytisk sammensetning og anvendelse derav | |
FI932390A0 (fi) | Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning | |
HUP9803018A2 (hu) | Ciklooxigenáz-2 gátló hatású vegyületek alkalmazása tumorok, tumorral kapcsolatos rendellenességek és cachexia kezelésére alkalmas gyógyszerkészítmények előállítására | |
HUP0402422A2 (hu) | Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HUP0402577A2 (hu) | Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra | |
RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
HUP0302068A2 (hu) | COX-2 inhibitorok alkalmazása immundeficienciával járó rendellenességek kezelésére vagy megelőzésére és ezeket tartalmazó gyógyszerkészítmények | |
ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
BR0315820A (pt) | Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização | |
EP0620737B1 (en) | Use of LACTOFERRIN iN the manufacture of a medicament for treating RHEUMATISM | |
NO306395B1 (no) | Tilidindihydrogenortofosfat, fremgangsmaate for dets fremstilling og farmasöytiske preparater inneholdende forbindelsen samt anvendelser derav | |
EA200400709A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
HUP9903928A2 (hu) | Fenoxi-etil-amin új származékai,eljárás előállításukra, alkalmazásuk gyógyszerhatóanyagokként és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
TH49153B (th) | ยานำ (prodrug) ของสารยับยั้งแอสพาร์ทิลโปรทีเอส |